A Senate panel has advanced three sets of bipartisan bills purportedly aimed at reforming the intellectual property (IP) ...

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

The president said he would build on the Medicare drug-price negotiation program begun under Joe Biden, but supports a change ...

The action directs the Food and Drug Administration to facilitate approval of state importation programs and to streamline ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like ...

Panelists discuss how hesitancy in prescribing amyloid-targeting therapies stems from multiple factors including concerns about ARIA adverse effects, modest clinical efficacy data, high treatment ...

The data showed no clinically meaningful differences between the biosimilar and the reference product in terms of safety, efficacy, immunogenicity and ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd has received U.S. Food and Drug Administration (U.S. FDA) approval for its Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous ...

“We are committed to generating more relevant and meaningful data to continually build confidence in biosimilars and contribute to a sustainable healthcare ecosystem worldwide.” About the Budget ...

Companies with a bigger share of biosimilars, specialty medicines and ... would lose market share in the US as their capability to build capacities in the US is no match against the giant ...